The table below shows Dyne Therapeutics, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Operating cash flow
-$403.21M
-$292.37M
-$188.16M
-$153.65M
-$119.56M
-$46.51M
Capital expenditure
$1.92M
$2.38M
$729.00K
$3.07M
$3.62M
$1.16M
Investing cash flow
-$28.75M
-$204.08M
$83.31M
$87.20M
-$137.89M
-$45.66M
Dividends paid
-
-
-
-
DYN operating cash flow (10-K history)
Dyne Therapeutics, Inc. reported operating cash flow of -$403.21M for fiscal year 2025. That is down 37.9% from -$292.37M in fiscal 2024. Over the 7 fiscal years shown, operating cash flow declined from -$11.83M (FY 2019) to -$403.21M. Figures come from the company's audited annual reports as filed with the SEC.
